Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

We recently reported that a DNA plasmid coding p62-SQSTM1 acts as an effective anti tumor vaccine against both transplantable mouse tumors and canine spontaneous mammary neoplasms. Here we report the unexpected finding that intramuscular delivery of p62 DNA exerts a powerful anti-osteoporotic activity in a mouse model of inflammatory bone loss (i.e, ovariectomy) by combining bone-sparing and osteo-synthetic effects. Notably, the suppression of osteoporosis by p62DNA was associated with a sharp down-regulation of master inflammatory cytokines, and up-regulation of endogenous p62 protein by bone-marrow stromal cells. The present data provide a solid rational to apply p62 DNA vaccine as a safe, new therapeutic for treatment of inflammatory related bone loss diseases.

Original publication

DOI

10.18632/oncotarget.2884

Type

Journal article

Journal

Oncotarget

Publication Date

28/02/2015

Volume

6

Pages

3590 - 3599

Keywords

Adaptor Proteins, Signal Transducing, Animals, Anti-Inflammatory Agents, Cloning, Molecular, DNA, Female, Humans, Injections, Intramuscular, Mice, Mice, Inbred BALB C, Plasmids, Random Allocation, Sequestosome-1 Protein, Vaccines, DNA